Bio + Healthcare
Portfolio spotlight
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
Milestones
- 2012 → Founded
- 2019 → Partnered, Series C
Partner
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
Milestones
- 2019 → Founded
- 2019 → Partnered, Seed
Partner
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
Milestones
- 2014 → Founded
- 2019 → Partnered, Series C
Partner
NASDAQ: GILD Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.
Milestones
- 1987 → Founded
- 1987 → Incubated by Menlo Ventures
- 1992 → IPO; NASDAQ: GILD
Partner
Acquired by Amazon PillPack is a full-service pharmacy that delivers a better, simpler experience through convenient packaging, modern technology, and personalized service.
Milestones
- 2013 → Founded
- 2015 → Partnered, Series C
- 2018 → Acquired by Amazon
Partner
NASDAQ: PLRX Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Milestones
- 2015 → Founded
- 2018 → Partnered, Series B
- 2020 → IPO; NASDAQ: PLRX
Partner
NASDAQ: RXRX Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
Milestones
- 2013 → Founded
- 2017 → Partnered, Series B
- 2021 → IPO; NASDAQ: RXRX
Partner
Our perspective
Eleos is the leader in CareOps Automation for behavioral health and joins Menlo Ventures’ exciting portfolio of healthcare software and AI companies.
The single greatest health concern facing American kids and teens today is a crisis in mental health.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.
Riva Health founders Tuhin Sinha and Dag Kittlaus discuss their critical mission to revolutionize cardiovascular healthcare; their long histories with Menlo partners Greg Yap and Shawn Carolan; how they were introduced to each other; and the whirlwind journey to FDA approval.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Cancer remains one of the leading causes of death in the U.S. and worldwide.
Ophelia is reinventing addiction treatment and dramatically improving access to best-in-class care with telemedicine.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Riva’s mission is to improve cardiovascular disease worldwide using just the smartphones that people already have in their pockets, replacing 130-year-old blood pressure cuff technology.
Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.
